AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients
13 December 2013 | By AstraZeneca
Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter...